| Female, no. (%) |
86 (86) |
| Age, mean +/− S.E., years |
35.8 ± 1.1 |
| Race, African American/Hispanic/Caucasian, no. |
45/42/13 |
| SLEDAI, median (interquartile) |
10 (4–16) |
| Renal SLEDAI, median (interquartile) |
4 (4–8) |
| No. of patients with renal SLEDAI = 0 (%) |
20 (20) |
| Protein:creatinine ratio, mg/mg, mean +/− S.E. |
2.0 ± 0.3 |
| Serum Cr, mg/dl, mean +/− S.E. |
1.5 ± 0.1 |
| Comorbidities, no. (%) |
|
| Diabetes Mellitus |
10 (10) |
| Hypertension |
75 (75) |
| Dyslipidemia |
58 (58) |
| Cardiovascular disease |
13 (13) |
| Anemia |
67 (67) |
| Antiphospholipid syndrome |
2 (2) |
| Venous thromboembolism |
8 (8) |
| Others |
50 (50) |
| Current medications, no. (%) |
|
| Prednisone |
71 (71) |
| Mycophenolic acid |
36 (36) |
| Cyclophosphamide |
7 (7) |
| Azathioprine/MTX |
13 (13) |
| Cyclosporine/Tacrolimus |
3 (3) |
| Hydroxychloroquine |
47 (47) |
| Angiotensin blocking agents |
49 (49) |
